NEJM -- Table of Contents (February 22 1990, 322 [8])

	Previous	Volume 322		February 22, 1990		Number 8	Next

Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors
R. C. Ash and Others
Abstract

A randomized trial of surgery in the treatment of single metastases to the brain
R. A. Patchell and Others
Abstract

Increase in glomerular filtration rate in patients with insulin-dependent diabetes and elevated erythrocyte sodium-lithium countertransport
S. Carr and Others
Abstract

Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis
M. A. Luzar and Others
Abstract

T-lymphocyte-antigen interactions in transplant rejection
A. M. Krensky and Others

Propafenone
C. Funck-Brentano, H. K. Kroemer, J. T. Lee, and D. M. Roden

Genetic linkage of a polymorphism in the type II procollagen gene (COL2A1) to primary osteoarthritis associated with mild chondrodysplasia
R. G. Knowlton and Others

Surgery for metastases to the brain
J. B. Posner

The doctor-nurse game revisited
L. I. Stein, D. T. Watts, and T. Howell

Canada's health care system faces its problems
J. K. Iglehart

Weekly clinicopathological exercises. Case 8-1990. A 45-year-old woman with Hodgkin's disease and a neurologic disorder

The ethics of liver transplantation from a living donor
A. Spital and M. Spital

Nonresponse to hepatitis B vaccine

Autosomal dominant spondyloarthropathy: no linkage to the type II collagen gene
A. Superti-Furga and Others

Reduction of nosocomial infection during pediatric intensive care by protective isolation
R. A. Garibaldi

Can maternal alcoholism cause spasmus nutans in offspring?
P. F. Bray

A caution about the use of MRI to diagnose spinal cord compression
J. A. Bonner and A. S. Lichter

Relations between physicians and pharmaceutical companies: where to draw the line
M. A. Jenike

[Note: This page was generated from the Medline data base.
There may be some discrepancies between the page shown and the original printed version.]

Comments and questions? Please contact us.